title: [Study of the effectiveness of recombinant alpha2-interferon and its inducers in primates with orthopoxvirus infection].
abstract: The interferon-inducing and antiviral activities of high-molecular interferon inducers larifan and rifastin and of gene engineering human alpha 2-interferon were studied in monkeys infected with smallpox. These agents appreciably prolonged the life span of infected monkeys. For green monkeys the drug efficacies were as follows: larifan protected 50%, rifastin 86%, and realderon 50% (if used for treatment) and 80% (if used for urgent prophylaxis) of animals from death; for Papio hamadryas the efficacy of urgent prophylaxis was 60%. Interferon accumulated in the serum as early as during the first hours after injection of interferon inducers, the peak concentrations being observed after 3-6 h; for realderone the peak was observed after 9 h. The levels of interferon induction with larifan and rifastin were virtually the same.
authors.forename: S Ia
authors.initials: SIa
authors.lastname: Loginova
authors.forename: G V
authors.initials: GV
authors.lastname: Bogatikov
authors.forename: A V
authors.initials: AV
authors.lastname: Prikhod'ko
authors.forename: A I
authors.initials: AI
authors.lastname: Polozov
mesh_terms: D000818:Animals; D000998:Antiviral Agents / Q000627:therapeutic use; D002642:Chick Embryo; D002522:Chlorocebus aethiops; D006801:Humans; D007369:Interferon Inducers / Q000627:therapeutic use*; D007370:Interferon Type I / Q000627:therapeutic use*; D009930:Organic Chemicals; D010215:Papio; D011994:Recombinant Proteins; D012899:Smallpox / Q000188:drug therapy*
chemical_list: D000998:Antiviral Agents; D007369:Interferon Inducers; D007370:Interferon Type I; D009930:Organic Chemicals; D011994:Recombinant Proteins; C066530:larifan